Aims and Scope of Anti-Cancer Drugs
Anti-Cancer Drugs is an international medical journal, which aims to promote and encourage research on anti-cancer agents. It was first published in 1990 and it includes reports on clinical and experimental research results, from conventional cytotoxic chemotherapy to hormonal or biological response modalities. The journal has 10 issues per year and the current editor in chief is Mels Sluyser. According to the 2014 Journal Citation Reports, the journal has an impact factor of 1.784, ranking it 164th out of 211 in the category Oncology and 162nd out of 254 in the category Pharmacology & Pharmacy. Less
Key Metrics
CiteScore 

5.2
H-Index 

98
Impact Factor 

< 5
SJR 

Q3Oncology

SNIP 

0.52
Recommended pre-submission checks
Powered by 

Topics Covered on Anti-Cancer Drugs
Anti-Cancer Drugs Journal Specifications
| Overview | |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1990 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Anti-Cancer Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Anti-Cancer Drugs
The novel integrin-linked kinase inhibitor nilotinib suppresses cancer progression by promoting ubiquitylation of autoimmune regulator in oesophageal squamous cell carcinoma
- 28 Apr 2026
- Anti-Cancer Drugs
Successful treatment of hairy cell leukemia with TP53 abnormality using cladribine combined with low-dose rituximab: a case report and literature review.
- 7 Apr 2026
- Anti-cancer drugs
Treatment of HRD-positive elderly ovarian cancer patient: a case report
- 30 Mar 2026
- Anti-Cancer Drugs
Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis
- 30 Mar 2026
- Anti-Cancer Drugs
A novel HEAT repeat protein 5B anaplastic lymphoma kinase fusion in lung adenocarcinoma confers sensitivity to ensartinib.
- 17 Mar 2026
- Anti-cancer drugs
3-Aminoisoquinolines inhibit selectively phosphodiesterase 4B in KRAS-mutated colorectal cancer cell lines in-vitro and in-vivo.
- 10 Mar 2026
- Anti-cancer drugs
The novel integrin-linked kinase inhibitor nilotinib suppresses cancer progression by promoting ubiquitylation of autoimmune regulator in oesophageal squamous cell carcinoma
- 28 Apr 2026
- Anti-Cancer Drugs
Successful treatment of hairy cell leukemia with TP53 abnormality using cladribine combined with low-dose rituximab: a case report and literature review.
- 7 Apr 2026
- Anti-cancer drugs
Treatment of HRD-positive elderly ovarian cancer patient: a case report
- 30 Mar 2026
- Anti-Cancer Drugs
Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis
- 30 Mar 2026
- Anti-Cancer Drugs
A novel HEAT repeat protein 5B anaplastic lymphoma kinase fusion in lung adenocarcinoma confers sensitivity to ensartinib.
- 17 Mar 2026
- Anti-cancer drugs
3-Aminoisoquinolines inhibit selectively phosphodiesterase 4B in KRAS-mutated colorectal cancer cell lines in-vitro and in-vivo.
- 10 Mar 2026
- Anti-cancer drugs